Published in Br J Cancer on June 14, 2011
Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst (2015) 2.94
Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS One (2015) 1.42
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci (2011) 1.05
Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterol Res Pract (2014) 0.96
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer (2012) 0.94
A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol (2013) 0.94
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther (2012) 0.89
Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World J Gastroenterol (2014) 0.89
Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases. HPB (Oxford) (2013) 0.87
Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol (2016) 0.85
Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer. J Gastrointest Cancer (2013) 0.81
Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. Onco Targets Ther (2014) 0.81
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol (2014) 0.80
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. BMC Cancer (2015) 0.79
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC Cancer (2014) 0.78
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study. Invest New Drugs (2013) 0.78
Management of a patient with metastatic colorectal cancer and liver metastases. Case Rep Oncol Med (2014) 0.78
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). Int J Clin Oncol (2015) 0.78
Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer. Onco Targets Ther (2015) 0.77
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer (2016) 0.77
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer (2016) 0.77
Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis. PLoS One (2015) 0.77
Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer. Mol Clin Oncol (2013) 0.77
Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer. Onco Targets Ther (2013) 0.77
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer (2014) 0.77
Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. Onco Targets Ther (2015) 0.76
Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer. Adv Biomed Res (2016) 0.75
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions. Oncotarget (2016) 0.75
Management of a locally advanced rectal cancer in a patient who declined surgery. Gastrointest Cancer Res (2012) 0.75
A postauthorization survey to document the therapeutic management of oxaliplatin as a first-line chemotherapy regimen in South Africa in patients with metastatic colorectal cancer. Chemother Res Pract (2014) 0.75
Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate. BMC Cancer (2017) 0.75
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Crit Rev Oncol Hematol (2016) 0.75
Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis. Medicine (Baltimore) (2016) 0.75
Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol (2016) 0.75
Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. World J Surg Oncol (2012) 0.75
Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer. Case Rep Oncol (2013) 0.75
Transforming growth factor-β1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition. Oncol Lett (2017) 0.75
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). Int J Clin Oncol (2015) 0.75
Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN). Transl Oncol (2017) 0.75
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med (2005) 6.22
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol (2008) 5.78
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol (2001) 4.89
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol (2007) 4.14
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol (2008) 1.65
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer (2011) 1.51
Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer (2009) 1.12
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol (2008) 1.06
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
The elderly at home: health and social status. Health Trends (1984) 5.23
Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem (1987) 4.99
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol (2001) 4.89
Functional assessment, curricular revision, and severe behavior problems. J Appl Behav Anal (1991) 4.53
Widespread occurrence of three sequence motifs in diverse S-adenosylmethionine-dependent methyltransferases suggests a common structure for these enzymes. Arch Biochem Biophys (1994) 4.06
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
RNA and protein interactions modulated by protein arginine methylation. Prog Nucleic Acid Res Mol Biol (1998) 3.67
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med (1996) 3.63
Membrane receptors for aspartate and serine in bacterial chemotaxis. J Biol Chem (1979) 3.61
Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem (1993) 3.52
Choice making to promote adaptive behavior for students with emotional and behavioral challenges. J Appl Behav Anal (1994) 3.50
Sequence of the D-aspartyl/L-isoaspartyl protein methyltransferase from human erythrocytes. Common sequence motifs for protein, DNA, RNA, and small molecule S-adenosylmethionine-dependent methyltransferases. J Biol Chem (1989) 3.16
Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum (2004) 3.12
The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. J Biol Chem (1996) 3.04
Changes in conserved region 2 of Escherichia coli sigma 70 affecting promoter recognition. J Mol Biol (1990) 3.04
Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A (2001) 3.04
The size and detergent binding of membrane proteins. J Biol Chem (1975) 2.82
beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A (1993) 2.80
PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J Biol Chem (2001) 2.67
Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg (2000) 2.60
Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. J Cell Physiol (1988) 2.59
DTI mapping of human brain connectivity: statistical fibre tracking and virtual dissection. Neuroimage (2003) 2.56
S-Adenosylmethionine-dependent methylation in Saccharomyces cerevisiae. Identification of a novel protein arginine methyltransferase. J Biol Chem (1999) 2.54
Structure of Thermotoga maritima stationary phase survival protein SurE: a novel acid phosphatase. Structure (2001) 2.43
Using assessment-based curricular intervention to improve the classroom behavior of a student with emotional and behavioral challenges. J Appl Behav Anal (1994) 2.41
Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol (1998) 2.36
PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. J Biol Chem (1998) 2.35
Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest (1998) 2.35
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol (1992) 2.31
PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem (2000) 2.26
Brain G protein gamma subunits contain an all-trans-geranylgeranylcysteine methyl ester at their carboxyl termini. Proc Natl Acad Sci U S A (1990) 2.26
Nonspecific bronchial reactivity in occupational asthma. J Allergy Clin Immunol (1979) 2.22
The Saccharomyces cerevisiae STE14 gene encodes a methyltransferase that mediates C-terminal methylation of a-factor and RAS proteins. EMBO J (1991) 2.20
Arginine methylation inhibits the binding of proline-rich ligands to Src homology 3, but not WW, domains. J Biol Chem (2000) 2.20
Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins. J Biol Chem (1989) 2.18
Postoperative visual loss following prone spinal surgery. Br J Anaesth (2005) 2.16
Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst (1998) 2.12
Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol (2008) 2.06
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol (1992) 1.98
The predominant protein-arginine methyltransferase from Saccharomyces cerevisiae. J Biol Chem (1996) 1.96
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol (2004) 1.95
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol (1999) 1.92
Distinct pathways involved in sound recognition and localization: a human fMRI study. Neuroimage (2001) 1.85
Cytochrome oxidase, acetylcholinesterase, and NADPH-diaphorase staining in human supratemporal and insular cortex: evidence for multiple auditory areas. Neuroimage (1997) 1.85
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol (1999) 1.84
An immunodeficiency characterized by defective signal transduction in T lymphocytes. N Engl J Med (1989) 1.79
The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet (2002) 1.77
Deficiency of a protein-repair enzyme results in the accumulation of altered proteins, retardation of growth, and fatal seizures in mice. Proc Natl Acad Sci U S A (1997) 1.75
A gene at 59 minutes on the Escherichia coli chromosome encodes a lipoprotein with unusual amino acid repeat sequences. J Bacteriol (1994) 1.75
Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee. Rheumatology (Oxford) (2005) 1.73
Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J (2007) 1.72
Protein carboxyl methyltransferases: two distinct classes of enzymes. Annu Rev Biochem (1985) 1.71
In vivo differential prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits. J Biol Chem (1992) 1.68
Farnesyl cysteine C-terminal methyltransferase activity is dependent upon the STE14 gene product in Saccharomyces cerevisiae. Mol Cell Biol (1990) 1.67
Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford) (2000) 1.67
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol (2012) 1.65
Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol (2001) 1.64
Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol (1986) 1.64
A large 4 pi plastic scintillator-detector with clinical applications. Int J Appl Radiat Isot (1967) 1.62
Two types of auditory neglect. Brain (2001) 1.62
Methods for the quantification of DNA double-strand breaks determined from the distribution of DNA fragment sizes measured by pulsed-field gel electrophoresis. Radiat Res (1995) 1.61
N-terminal methylation of proteins: structure, function and specificity. FEBS Lett (1987) 1.59
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol (2007) 1.58
Household income and health care expenditures in Mexico. Health Policy (1997) 1.58
Reaction of systemic lupus erythematosus antinative DNA antibodies with native DNA fragments from 20 to 1,200 base pairs. J Clin Invest (1980) 1.57
Informed consent and general surgeons' attitudes toward the use of pain medication in the acute abdomen. Am J Emerg Med (1999) 1.55
spoIID operon of Bacillus subtilis: cloning and sequence. J Gen Microbiol (1986) 1.54
Patients with advanced cancer: a survey of the understanding of their illness and expectations from palliative radiotherapy for symptomatic metastases. Clin Oncol (R Coll Radiol) (2001) 1.53
Identification of a C-terminal protein carboxyl methyltransferase in rat liver membranes utilizing a synthetic farnesyl cysteine-containing peptide substrate. J Biol Chem (1990) 1.51
Pain in clinical oncology: patient satisfaction with management of cancer pain. Eur J Pain (2011) 1.51
Association between Helicobacter pylori infection and pancreatic cancer. Oncology (1998) 1.49
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol (2004) 1.49
Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Ann Oncol (2009) 1.48
Current indications and results of VATS in the evaluation and management of hemodynamically stable thoracic injuries. Eur J Cardiothorac Surg (2004) 1.48
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer (2003) 1.48
Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol (1996) 1.48
Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types. Infect Immun (1983) 1.46
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol (2004) 1.46
RpoS- and OxyR-independent induction of HPI catalase at stationary phase in Escherichia coli and identification of rpoS mutations in common laboratory strains. J Bacteriol (1997) 1.46
Protein carboxyl methyltransferase facilitates conversion of atypical L-isoaspartyl peptides to normal L-aspartyl peptides. J Biol Chem (1987) 1.46
Conversion of isoaspartyl peptides to normal peptides: implications for the cellular repair of damaged proteins. Proc Natl Acad Sci U S A (1987) 1.44
Membrane-binding domain of the small G protein G25K contains an S-(all-trans-geranylgeranyl)cysteine methyl ester at its carboxyl terminus. Proc Natl Acad Sci U S A (1991) 1.43
Protein phosphatase 2A is reversibly modified by methyl esterification at its C-terminal leucine residue in bovine brain. J Biol Chem (1994) 1.43
Isolated liver transplant in infants with short bowel syndrome: insights into outcomes and prognostic factors. J Pediatr Gastroenterol Nutr (2009) 1.42
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie (2003) 1.41
The protein carboxylmethyltransferase involved in Escherichia coli and Salmonella typhimurium chemotaxis. Methods Enzymol (1984) 1.41
Death from metastatic donor-derived ovarian cancer in a male kidney transplant recipient. Am J Transplant (2009) 1.41
Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum (1997) 1.41
Infective crystalline keratopathy secondary to non-tuberculous mycobacterium (Mycobacterium abscessus) in a non-traumatized eye. Eye (Lond) (2007) 1.40